{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:12:38Z","timestamp":1792033958106,"version":"4.4.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010651","name":"Fujian Normal University","doi-asserted-by":"publisher","award":["Z0210509"],"award-info":[{"award-number":["Z0210509"]}],"id":[{"id":"10.13039\/501100010651","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301403"],"award-info":[{"award-number":["2021YFC2301403"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172287"],"award-info":[{"award-number":["82172287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82225028"],"award-info":[{"award-number":["82225028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803547"],"award-info":[{"award-number":["81803547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J01204"],"award-info":[{"award-number":["2021J01204"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopha.2024.117179","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T08:51:32Z","timestamp":1721983892000},"page":"117179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Advances in small-molecule insulin secretagogues for diabetes treatment"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-7177","authenticated-orcid":false,"given":"Jingqian","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117179_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115734","article-title":"Diabetes mellitus: classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments","volume":"168","author":"Antar","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.117179_bib2","doi-asserted-by":"crossref","first-page":"m4743","DOI":"10.1136\/bmj.m4743","article-title":"Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data","volume":"372","author":"Goldenberg","year":"2021","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s00125-021-05415-5","article-title":"Defining the underlying defect in insulin action in type 2 diabetes","volume":"64","author":"Batista","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2024.117179_bib4","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.2147\/DMSO.S319895","article-title":"A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives","volume":"14","author":"Reed","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2024.117179_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"17","key":"10.1016\/j.biopha.2024.117179_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713381","article-title":"Advances in research on Type 2 diabetes mellitus targets and therapeutic agents","volume":"24","author":"Su","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","article-title":"Global trends in diabetes complications: a review of current evidence","volume":"62","author":"Harding","year":"2019","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib8","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/dom.14418","article-title":"Technology in the management of type 2 diabetes: present status and future prospects","volume":"23","author":"Daly","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020331","article-title":"Exploring new drug targets for type 2 diabetes: success, challenges and opportunities","volume":"10","author":"Kanwal","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.biopha.2024.117179_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41573-023-00713-6","article-title":"Small-molecule discovery through DNA-encoded libraries","volume":"22","author":"Peterson","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2024.117179_bib12","article-title":"Natural medicines of targeted rheumatoid arthritis and its action mechanism","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084476","article-title":"Research progress on anti-inflammatory effects and related mechanisms of astragalin","volume":"25","author":"Ruan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41467-022-28435-0","article-title":"Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes","volume":"13","author":"Gunasekar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.117179_bib15","doi-asserted-by":"crossref","first-page":"1175660","DOI":"10.3389\/fnut.2023.1175660","article-title":"Therapeutic potential of multifunctional myricetin for treatment of type 2 diabetes mellitus","volume":"10","author":"Niisato","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.biopha.2024.117179_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: an update and future directions","volume":"137","author":"Demarsilis","year":"2022","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib17","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2337\/dbi23-0032","article-title":"Glucose regulation of beta-cell KATP channels: it is time for a new model","volume":"73","author":"Merrins","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.117179_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-pharmtox-051921-123023","article-title":"Personalized therapeutics for KATP-dependent pathologies","volume":"63","author":"Nichols","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/cpt.2570","article-title":"Sulfonylureas and the risk of ventricular arrhythmias among people with type 2 diabetes: a systematic review of observational studies","volume":"111","author":"Islam","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib20","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1210\/clinem\/dgab151","article-title":"The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function","volume":"106","author":"Cordiner","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/dom.14740","article-title":"Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: results of the LEGEND-A pilot study","volume":"24","author":"Spiliotis","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2024.117179_bib22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.14875","article-title":"A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults","volume":"25","author":"Halvorsen","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2024.117179_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45854","article-title":"Comparison of mitochondrial adenosine triphosphate-sensitive potassium channel high- vs low-affinity sulfonylureas and cardiovascular outcomes in patients with type 2 diabetes treated with metformin","volume":"5","author":"Wang","year":"2022","journal-title":"Jama Netw. Open"},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib25","article-title":"Metformin for preventing the progression of chronic kidney disease","volume":"6","author":"El-Damanawi","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2024.117179_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.754123","article-title":"The anti-diabetic drug gliquidone modulates lipopolysaccharide-mediated microglial neuroinflammatory responses by inhibiting the NLRP3 inflammasome","volume":"13","author":"Kim","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.biopha.2024.117179_bib27","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahlen","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/dom.13941","article-title":"Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon","volume":"22","author":"Thieu","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib29","article-title":"Metformin monotherapy for adults with type 2 diabetes mellitus","volume":"6","author":"Gnesin","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2024.117179_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.735824","article-title":"Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/obr.12753","article-title":"Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials","volume":"20","author":"Jia","year":"2019","journal-title":"Obes. Rev."},{"issue":"Suppl 3","key":"10.1016\/j.biopha.2024.117179_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.biopha.2024.117179_bib33","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2024.117179_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz175","article-title":"GIP and GLP-1 receptor antagonism during a meal in healthy individuals","volume":"105","author":"Gasbjerg","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.117179_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.117179_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2024.117179_bib38","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41422-020-0384-8","article-title":"Structural insights into the activation of GLP-1R by a small molecule agonist","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"issue":"7790","key":"10.1016\/j.biopha.2024.117179_bib39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-019-1902-z","article-title":"Activation of the GLP-1 receptor by a non-peptidic agonist","volume":"577","author":"Zhao","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bph.16278","article-title":"Newer pharmacological interventions directed at gut hormones for obesity","volume":"181","author":"Camilleri","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.biopha.2024.117179_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200155119","article-title":"Structural basis of peptidomimetic agonism revealed by small- molecule GLP-1R agonists Boc5 and WB4-24","volume":"119","author":"Cong","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib42","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bph.15647","article-title":"Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting?","volume":"179","author":"Borner","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3803\/EnM.2021.102","article-title":"Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists","volume":"36","author":"Choe","year":"2021","journal-title":"Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.biopha.2024.117179_bib44","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41589-020-0589-7","article-title":"Structural insights into probe-dependent positive allosterism of the GLP-1 receptor","volume":"16","author":"Bueno","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.117179_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/bs.apha.2020.02.001","article-title":"Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: a novel tool to probe GLP-1R pharmacology","volume":"88","author":"Willard","year":"2020","journal-title":"Adv. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101889","article-title":"Design, synthesis, and biological evaluation of a small molecule oral agonist of the glucagon-like-peptide-1 receptor","volume":"298","author":"Girdhar","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib47","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1021\/acs.jmedchem.1c01842","article-title":"Discovery of V-0219: a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor toward oral treatment for \"Diabesity\"","volume":"65","author":"Decara","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117179_bib48","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2147\/DDDT.S404055","article-title":"Cinchonine, a potential oral small-molecule glucagon-like peptide-1 receptor agonist, lowers blood glucose and ameliorates non-alcoholic steatohepatitis","volume":"17","author":"Xue","year":"2023","journal-title":"Drug Des. Devel Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.15383","volume":"26","author":"Wu","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"47","key":"10.1016\/j.biopha.2024.117179_bib50","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib51","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"issue":"12","key":"10.1016\/j.biopha.2024.117179_bib53","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/dom.14928","article-title":"A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus","volume":"25","author":"Ono","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.biopha.2024.117179_bib55","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"Jama Netw. Open"},{"key":"10.1016\/j.biopha.2024.117179_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116965","article-title":"Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112","volume":"177","author":"Sun","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib58","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/dme.14325","article-title":"Inhibitors of dipeptidyl peptidase-4 as therapeutic agents for individuals with type 2 diabetes: a 25-year journey","volume":"37","author":"Carr","year":"2020","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2024.117179_bib59","article-title":"Emerging role of dipeptidyl peptidase-4 in autoimmune disease","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2024.117179_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165933","article-title":"DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice","volume":"133","author":"Herman","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2024.117179_bib61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"13","key":"10.1016\/j.biopha.2024.117179_bib62","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1021\/acs.jmedchem.0c00374","article-title":"Design, synthesis, and evaluation of a series of novel super long-acting DPP-4 inhibitors for the treatment of type 2 diabetes","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2024.117179_bib63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2024.117179_bib64","article-title":"Effect of CYP3A4 inhibitors and inducers on pharmacokinetics and pharmacodynamics of saxagliptin and active metabolite M2 in humans using physiological-based pharmacokinetic combined DPP-4 occupancy","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117179_bib65","article-title":"First-in-human, double-blind, randomized, placebo-controlled trial of TQ-F3083, a new dipeptidyl peptidase-4 inhibitor, in healthy chinese adults","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117179_bib66","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/dom.14810","article-title":"Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: a 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial","volume":"24","author":"Xu","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02670-9","article-title":"Cardiovascular outcomes of type 2 diabetic patients treated with DPP\u20114 inhibitors versus sulphonylureas as add-on to metformin in clinical practice","volume":"11","author":"Bazo-Alvarez","year":"2021","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib68","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes","volume":"42","author":"Douros","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib70","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American college of physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib71","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"Jama Intern. Med."},{"issue":"11","key":"10.1016\/j.biopha.2024.117179_bib72","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1210\/clinem\/dgac540","article-title":"Association between DPP4 inhibitor use and the incidence of cirrhosis, ESRD, and some cancers in patients with diabetes","volume":"107","author":"Na","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.117179_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119574","article-title":"DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity","volume":"278","author":"Yeh","year":"2021","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.biopha.2024.117179_bib74","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJMoa2200433","article-title":"Glycemia reduction in type 2 diabetes - glycemic outcomes","volume":"387","author":"Nathan","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib75","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: a prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib76","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-022-27301-9","article-title":"Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study","volume":"13","author":"Nagao","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117179_bib77","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3389\/fendo.2019.00780","article-title":"Insights into GLP-1 and GIP actions emerging from vildagliptin mechanism studies in man","volume":"10","author":"Foley","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072275","article-title":"Vasculoprotective effects of vildagliptin. Focus on atherogenesis","volume":"21","author":"Wicinski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071573","article-title":"Saxagliptin cardiotoxicity in chronic heart failure: the role of DPP4 in the regulation of neuropeptide tone","volume":"10","author":"Voros","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142243","article-title":"Pharmacological treatment of hyperglycemia in type 2 diabetes","volume":"131","author":"Taylor","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.biopha.2024.117179_bib81","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s40264-019-00857-8","article-title":"Benefit-risk assessment of alogliptin for the treatment of type 2 diabetes mellitus","volume":"42","author":"Kaku","year":"2019","journal-title":"Drug. Saf."},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib82","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/dom.14661","volume":"24","author":"Gao","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib83","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jamacardio.2023.4602","article-title":"Hypoglycemia and cardiovascular outcomes in the CARMELINA and CAROLINA trials of linagliptin: a secondary analysis of randomized clinical trials","volume":"9","author":"Marx","year":"2024","journal-title":"Jama Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib84","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","article-title":"Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial","volume":"11","author":"Laffel","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117179_bib85","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1080\/00498254.2021.1963010","article-title":"In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers","volume":"51","author":"Lu","year":"2021","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.biopha.2024.117179_bib86","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40261-021-01088-5","article-title":"First-in-human, single-ascending dose and food effect studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of cetagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus","volume":"41","author":"Wang","year":"2021","journal-title":"Clin. Drug Investig."},{"issue":"6","key":"10.1016\/j.biopha.2024.117179_bib87","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1111\/bcp.15209","article-title":"A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin","volume":"88","author":"Lu","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib88","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10051060","article-title":"Assessing the effect of incretin hormones and other insulin secretagogues on pancreatic beta-cell function: review on mathematical modelling approaches","volume":"10","author":"Pacini","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib90","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/pharmrev.120.000082","article-title":"Post-translational modifications of G protein-coupled receptors control cellular signaling dynamics in space and time","volume":"73","author":"Patwardhan","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib91","doi-asserted-by":"crossref","first-page":"C583","DOI":"10.1152\/ajpcell.00464.2021","article-title":"Recent progress in assays for GPCR drug discovery","volume":"323","author":"Guo","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib92","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/pharmrev.123.001015","article-title":"The role of G protein-coupled receptors and receptor kinases in pancreatic beta-cell function and diabetes","volume":"76","author":"Varney","year":"2024","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/j.biopha.2024.117179_bib93","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41575-023-00830-y","article-title":"The intestine as an endocrine organ and the role of gut hormones in metabolic regulation","volume":"20","author":"Bany","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2024.117179_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104998","article-title":"GPR119 agonists: novel therapeutic agents for type 2 diabetes mellitus","volume":"113","author":"Manaithiya","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib95","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41574-020-00459-w","article-title":"Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges","volume":"17","author":"Ghislain","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117179_bib96","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41594-022-00816-5","article-title":"Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119","volume":"29","author":"Xu","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.biopha.2024.117179_bib97","doi-asserted-by":"crossref","DOI":"10.2174\/1389557523666230302140658","article-title":"Structural insight on GPR119 agonist as potential therapy for type II diabetes: a comprehensive review","author":"Nema","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib98","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/13543784.2024.2321271","article-title":"GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates","volume":"33","author":"Hryciw","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9","key":"10.1016\/j.biopha.2024.117179_bib99","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/13543776.2021.1921152","article-title":"GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)","volume":"31","author":"Li","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.biopha.2024.117179_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116208","article-title":"Discovery of a novel series of GPR119 agonists: design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives","volume":"41","author":"Kubo","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117179_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116034","article-title":"Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach","volume":"34","author":"Kamaura","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117179_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112324","article-title":"A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression","volume":"144","author":"Kim","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4093\/dmj.2021.0056","article-title":"DA-1241, a Novel GPR119 agonist, improves hyperglycaemia by inhibiting hepatic gluconeogenesis and enhancing insulin secretion in diabetic mice","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.biopha.2024.117179_bib104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2017.02.043","article-title":"APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL\/6 mice","volume":"801","author":"Bahirat","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117179_bib105","doi-asserted-by":"crossref","first-page":"1310231","DOI":"10.3389\/fphar.2024.1310231","article-title":"Structure of human GPR119-Gs complex binding APD597 and characterization of GPR119 binding agonists","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib106","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41401-023-01215-2","article-title":"GPCRs involved in metabolic diseases: pharmacotherapeutic development updates","volume":"45","author":"Jin","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib107","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.118.250019","article-title":"DS-8500a, an orally available G protein-coupled receptor 119 agonist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats","volume":"367","author":"Matsumoto","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib108","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12325-018-0668-2","article-title":"Efficacy and safety of GPR119 Agonist DS-8500a in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study","volume":"35","author":"Yamada","year":"2018","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","article-title":"G protein-coupled receptors: structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52048-1","article-title":"GPR40 activation initiates store-operated Ca2+ entry and potentiates insulin secretion via the IP3R1\/STIM1\/Orai1 pathway in pancreatic \u03b2-cells","volume":"9","author":"Usui","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib111","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1152\/physrev.00041.2018","article-title":"Free fatty acid receptors in health and disease","volume":"100","author":"Kimura","year":"2020","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2024.117179_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101840","article-title":"Hypothalamic free fatty acid receptor-1 regulates whole-body energy balance","volume":"79","author":"Dragano","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.117179_bib113","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1016\/j.csbj.2021.07.008","article-title":"Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations","volume":"19","author":"An","year":"2021","journal-title":"Comp. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2024.117179_bib114","doi-asserted-by":"crossref","first-page":"1043828","DOI":"10.3389\/fphar.2022.1043828","article-title":"Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders","volume":"13","author":"Guan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117179_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101757","article-title":"Free fatty acid receptor 1 stimulates cAMP production and gut hormone secretion through Gq-mediated activation of adenylate cyclase 2","volume":"74","author":"Petersen","year":"2023","journal-title":"Mol. Metab."},{"issue":"14","key":"10.1016\/j.biopha.2024.117179_bib116","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1073\/pnas.1811066116","article-title":"Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40\/FFAR1","volume":"116","author":"Luckmann","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2024.117179_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115990","article-title":"Synthetic GPR40\/FFAR1 agonists: an exhaustive survey on the most recent chemical classes and their structure-activity relationships","volume":"264","author":"Paul","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2024.117179_bib118","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2337\/db21-0451","article-title":"SCO-267, a GPR40 full agonist, stimulates islet and gut hormone secretion and improves glycemic control in humans","volume":"70","author":"Nishizaki","year":"2021","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib119","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1021\/acs.jmedchem.1c00031","article-title":"Structure-activity relationship study and biological evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic acid derivatives as GPR40 full agonists","volume":"64","author":"Zhao","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00498254.2020.1864510","article-title":"Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects","volume":"51","author":"Zhao","year":"2021","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib121","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/toxsci\/kfy253","article-title":"Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury","volume":"167","author":"Longo","year":"2019","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biopha.2024.117179_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115267","article-title":"Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into beta-position to the carboxylic acid","volume":"251","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117179_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110708","article-title":"Type II diabetes mellitus: a review on recent drug based therapeutics","volume":"131","author":"Padhi","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.117179_bib124","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-981-13-8719-7_10","article-title":"GPCR allosteric modulator discovery","volume":"1163","author":"Wu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","article-title":"Biased allosteric modulators: new frontiers in GPCR drug discovery","volume":"42","author":"Slosky","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib126","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acsmedchemlett.8b00213","article-title":"Discovery of AM-6226: a potent and orally bioavailable GPR40 full agonist that displays efficacy in nonhuman primates","volume":"9","author":"Brown","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib127","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","article-title":"Targeting metabolic dysregulation for fibrosis therapy","volume":"19","author":"Zhao","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2024.117179_bib128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cbi.2018.09.011","article-title":"Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice","volume":"296","author":"Urano","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biopha.2024.117179_bib129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2018.04.023","article-title":"Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker","volume":"152","author":"Chen","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.biopha.2024.117179_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512244","article-title":"G protein-coupled receptor 40 agonist LY2922470 alleviates ischemic-stroke-induced acute brain injury and functional alterations in mice","volume":"24","author":"Lu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib131","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/molpharm.120.000168","article-title":"Chronic exposure to SCO-267, an allosteric GPR40 full agonist, is effective in improving glycemic control in rats","volume":"99","author":"Koyama","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117179_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113810","article-title":"Discovery and development of CPL207280 as new GPR40\/FFA1 agonist","volume":"226","author":"Mach","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib133","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1124\/molpharm.121.000260","article-title":"CPL207280, a novel G protein-coupled receptor 40\/free fatty acid receptor 1-specific agonist, shows a favorable safety profile and exerts antidiabetic effects in type 2 diabetic animals","volume":"100","author":"Bazydlo-Guzenda","year":"2021","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22345","article-title":"Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolites","volume":"33","author":"Ackerson","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"22","key":"10.1016\/j.biopha.2024.117179_bib135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219569120","article-title":"Molecular mechanism of fatty acid activation of FFAR1","volume":"120","author":"Kumari","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2024.117179_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113709","article-title":"Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders","volume":"155","author":"Olloquequi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.117179_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113990","article-title":"Status of research on natural protein tyrosine phosphatase 1B inhibitors as potential antidiabetic agents: update","volume":"157","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2024.117179_bib138","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13105-021-00860-7","article-title":"The role of protein tyrosine phosphatase 1B (PTP1B) in the pathogenesis of type 2 diabetes mellitus and its complications","volume":"78","author":"Teimouri","year":"2022","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2024.117179_bib139","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejmech.2019.01.057","article-title":"Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors","volume":"166","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115263","article-title":"Anti-diabetic drugs recent approaches and advancements","volume":"28","author":"Dowarah","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib141","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1074\/jbc.C117.819110","article-title":"A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models","volume":"293","author":"Krishnan","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070866","article-title":"Computational methods in cooperation with experimental approaches to design protein tyrosine phosphatase 1B inhibitors in type 2 diabetes drug design: a review of the achievements of this century","volume":"15","author":"Campos-Almazan","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2024.117179_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104683","article-title":"Diarylheptanoid-chalcone hybrids with PTP1B and alpha-glucosidase dual inhibition from Alpinia katsumadai","volume":"108","author":"He","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2024.117179_bib144","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41392-022-01038-3","article-title":"Targeting protein phosphatases for the treatment of inflammation-related diseases: from signaling to therapy","volume":"7","author":"Pan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.117179_bib145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1021\/acs.jcim.8b00040","article-title":"Virtual screening of novel and selective inhibitors of protein tyrosine phosphatase 1B over T-cell protein tyrosine phosphatase using a bidentate inhibition strategy","volume":"58","author":"Chen","year":"2018","journal-title":"J. Chem. Inf. Model."},{"issue":"11","key":"10.1016\/j.biopha.2024.117179_bib146","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.celrep.2019.08.019","article-title":"Intranasal targeting of hypothalamic PTP1B and TCPTP reinstates leptin and insulin sensitivity and promotes weight loss in obesity","volume":"28","author":"Dodd","year":"2019","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.biopha.2024.117179_bib147","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/dci23-0021","article-title":"The growing role of technology in the care of older adults with diabetes","volume":"46","author":"Huang","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.biopha.2024.117179_bib148","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/endrev\/bnad037","article-title":"The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa","volume":"45","author":"Rosenstock","year":"2024","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2024.117179_bib149","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American college of physicians","volume":"177","author":"Drake","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2024.117179_bib150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117179_bib151","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40265-019-01086-0","article-title":"The unique pharmacological and pharmacokinetic profile of teneligliptin: implications for clinical practice","volume":"79","author":"Ceriello","year":"2019","journal-title":"Drugs"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:48:08Z","timestamp":1777862888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224010631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":151,"alternative-id":["S0753332224010631"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117179","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in small-molecule insulin secretagogues for diabetes treatment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117179"}}